Don’t miss – Page 190 – Endpoints News

SIGN UP

Feds add fraud charges to the multitude of accusations made against former MiMedx execs

4 years ago

Acadia's sweeping hunt for better Nuplazid data bags mixed results for schizophrenia

4 years ago

Make that 2 new sickle cell disease blockbuster hopefuls OK’d by the FDA in just a few days

4 years ago

‘Breakthrough’ bladder cancer drug spinout gets $570M to back launch of a new gene therapy in the US

4 years ago

Harvard consortium blueprints $50M cell and gene therapy center — but can they actually foster lower drug prices?

4 years ago

Acquisitive Novartis bags PCSK9 player MedCo for $9.7B, setting up a flank attack on Sanofi, Regeneron and Amgen

4 years ago

Celgene R&D vet jumps to biotech: 'It’s about shortening the cycle'; Novartis exodus continues as William Chou takes the helm at Aruvant

4 years ago

Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now

4 years ago

Ahead of strategic update, new Sanofi CEO mulls options for consumer healthcare arm — reports

4 years ago

The triple crown in biotech: An all-or-nothing bet on an FDA approval of 3 drugs over 16 months starts today

4 years ago

Make that 2 approved RNAi drugs at Alnylam after the FDA offers a speedy OK on ultra-rare disease drug

4 years ago

Eli Lilly touts $400M manufacturing expansion, 100 new jobs to much fanfare in Indianapolis — even though it's been chopping staff

4 years ago

London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund

4 years ago

Amgen chops 172 more staffers in R&D, operations and sales amid neuroscience exit, revenue downturn

4 years ago

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player Dragonfly

4 years ago

Novartis is eyeing a multibillion-dollar MedCo buyout as Jersey biotech nears NDA — reports

4 years ago

In a landmark first glimpse of human data from Vertex, CRISPR/Cas9 gene therapy signals early benefit

4 years ago

Alkermes forges $950M biotech buyout deal in a bold bet on an early-stage CNS drug platform

4 years ago

After a late-stage miss, Novartis touts another Entresto analysis to convince the FDA to expand the blockbuster's label

4 years ago

Novartis is axing 150 early discovery jobs as CNIBR shifts focus to the development side of R&D

4 years ago

Karuna clears PhII hurdle in schizophrenia, takes aim at a pivotal in blockbuster hunt — shares soar

4 years ago

FTC clears Bristol-Myers’ $74B deal to buy Celgene — but Dems signal a potential hard shift against Big Pharma M&A

4 years ago

Novartis scores its latest FDA OK — this time for a new sickle cell disease drug picked up in a $665M deal

4 years ago

Roche bags 'breakthrough' anti-fibrosis drug in $1.4B biotech buyout deal

4 years ago

First page Previous page 187 188 189190191 192 193 Next page Last page